Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-c3 and Bevacizumab ± Pembrolizumab in CCNE1 Amplified and TP53 Mutant Solid Tumors
NCT05431582Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of azenosertib in solid tumor, ovarian cancer, breast cancer and 2 more (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose at 1 year and Antitumor activity at 1 year. Planned start Dec 2022; status: withdrawn.
02
Drugs
azenosertib
03
Conditions
solid tumorovarian cancerbreast cancerlung cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05431582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431582.